The British-American multinational pharmaceutical company, GlaxoSmithKline plc’s antibody treatment sotrovimab, is said to be effective against all 37 variants of omicron. The one-time injection given into a vein leads to less than a three-fold drop in neutralization. Based on the findings of the study, the company asserted that sotrovimab can lead to fewer symptoms and reduce the risk of severe consequences of COVID-19. The antibody drug is given by a health care expert to people above the age of 12 years within 10 days of the initial infection. It is only used for mild or moderate cases. Sotrovimab is an FDA approved emergency medication used for treating patients with a high risk of developing coronavirus related complications due to added comorbidities like older age, obesity, or conditions like lung, kidney, or heart disease, diabetes.

Read more: Coronavirus: Will mixing COVID-19 vaccines provide higher immunity amid Omicron threat? Study explains

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *